IDEC’s 2000 Press Releases

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.

2003 | 2002 | 2001 | 2000 | 1999 Back to main index

12/05/2000

Final Results of the Two ZEVALIN Pivotal Trials in Radioimmunotherapy for B Cell Non-Hodgkins Lymphoma Announced by IDEC Pharmaceuticals At 42nd Annual Society of Hematology Meeting

11/16/2000

IDEC Pharmaceuticals Prices Public Offering

11/03/2000

IDEC Pharmaceuticals Announces Filing of a Registration Statement for 2,000,000 Shares of Common Stock

11/01/2000

IDEC Pharmaceuticals Submits Biologics License Application for ZEVALIN Radioimmunotherapy to the U.S. Food and Drug Administration

11/01/2000

IDEC Pharmaceuticals to Receive Peter McCuen Cancer Research Excellence Award From Informed Investors Inc.

10/16/2000

IDEC Pharmaceuticals Reports Third Quarter 2000 Results

08/07/2000

IDEC Pharmaceuticals Initiates Phase II Study With Primatized Antibody Clenoliximab in Patients With Rheumatoid Arthritis

08/01/2000

IDEC Pharmaceuticals Promotes Christine A. White, M.D., to Vice President, Clinical Oncology and Hematology

07/18/2000

IDEC Pharmaceuticals Reports Second Quarter 2000 Results

07/17/2000

IDEC Pharmaceuticals Announces U.S. Rituxan Sales of $ 96.7 Million in Second Quarter, 2000

06/28/2000

IDEC Pharmaceuticals and Taisho Announce Collaborative Agreement to Develop Antibodies Targeting Inflammatory & Autoimmune Diseases

05/23/2000

Preliminary and Updated Results of Four ZEVALIN Studies Presented at ASCO

04/20/2000

IDEC Pharmaceuticals Reports First Quarter 2000 Results

04/17/2000

IDEC Pharmaceuticals Expands Oncology Pipeline With Two Novel Investigational Immunotherapies for Prostate Cancer

04/12/2000

IDEC Pharmaceuticals Announces U.S. Rituxan Sales of $78 Million in First Quarter, 2000; 50 Percent Increase in Quarterly Sales Over 1st Quarter 1999

03/15/2000

IDEC Pharmaceuticals Announced Results of Phase I Study of Idec-114 Antibody in Psoriasis

02/22/2000

IDEC Pharmaceuticals Announces New Senior Vice President of Biopharmaceutical Sciences

02/03/2000

IDEC Pharmaceuticals Initiates Phase I Study With PRIMATIZED Antibody IDEC-152 in Patients With Allergic Asthma

02/02/2000

IDEC Pharmaceuticals Reports Second Year of Profitability On Revenue Growth of 36 Percent

01/20/2000

IDEC Pharmaceuticals Announces U.S. Rituxan Sales of $72.2 Million in Fourth Quarter, 1999, and $262.7 Million for the Full Year


2003 | 2002 | 2001 | 2000| 1999 Back to main index